DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Panafil (Papain / Urea / Chlorophyllin Topical) - Summary



PANAFIL Ointment is an enzymatic healing-debriding ointment which contains papain, USP (not less than 521,700 USP units of activity per gram); urea, USP 10%; and chlorophyllin copper complex sodium, USP 0.5% in a hydrophilic base composed of boric acid, chlorobutanol (anhydrous) as a preservative, polyoxyl 40 stearate, propylene glycol, purified water, sodium borate, sorbitanmonostearate, stearyl alcohol, and white petrolatum.

PANAFIL Ointment is suggested for treatment of acute and chronic lesions such as varicose, diabetic and decubitus ulcers, burns, postoperative wounds, pilonidal cyst wounds, carbuncles and miscellaneous traumatic or infected wounds.

PANAFIL Ointment is applied continuously throughout treatment of these conditions (1) for enzymatic debridement of necrotic tissue and liquefaction of fibrinous, purulent debris, (2) to keep the wound clean, and simultaneously (3) to promote normal healing.

See all Panafil indications & dosage >>


Published Studies Related to Panafil (Papain / Urea / Chlorophyllin)

Relative delivery efficiency and convenience of spray and ointment formulations of papain/urea/chlorophyllin enzymatic wound therapies. [2006.09]
OBJECTIVE: To determine the relative delivery efficiency and user preference for spray and ointment formulations containing papain, urea, and chlorophyllin copper complex sodium (papain/urea/chlorophyllin copper complex)... CONCLUSIONS: The spray formulation of papain/urea/chlorophyllin copper complex resulted in less product use per wound application than did 3 different ointment formulations. Participants expressed a favorable impression of practical benefits of the spray formulation including a reduced risk of wound contamination.

The effects of Panafil when using topical negative pressure to heal an infected sternal wound. [2004.11]
A wound that became infected a few weeks after bypass surgery responded well to a treatment regimen combining TNP with application of an enzymatic agent. The patient had diabetes mellitus, which slows healing and increases infection risk..

more studies >>

Page last updated: 2007-08-04

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017